High cholesterol absorption is associated with increased cardiovascular risk in haemodialysis patients: insights from

Günther Silbernagel1, Kévin Duarte2, Samir Sadiku3

  • 1Division of Angiology, Department of Internal Medicine, Medical University of Graz, Auenbruggerplatz 15, 8036 Graz, Austria.

Insights

Statin treatment did not prevent cardiovascular events in hemodialysis patients. High cholesterol absorption increases cardiovascular risk, but statin therapy does not benefit patients with high cholesterol absorption.

Area of Science:

  • Cardiovascular Medicine
  • Nephrology
  • Pharmacology

Background:

  • Cardiovascular disease (CVD) is a leading cause of mortality in patients undergoing hemodialysis.
  • Previous studies suggested statin therapy might reduce CVD risk in this population, but results have been inconsistent.
  • Cholesterol metabolism, including absorption and synthesis, plays a role in CVD pathogenesis.

Purpose of the Study:

  • To investigate the association between cholesterol absorption and synthesis rates and cardiovascular event risk in hemodialysis patients.
  • To determine if cholesterol metabolism markers predict response to statin therapy in this population.

Main Methods:

  • The AURORA trial was a randomized, double-blind, placebo-controlled study involving hemodialysis patients.
  • Participants received rosuvastatin or placebo, with follow-up for cardiovascular death.
  • Cholesterol absorption and synthesis were estimated using cholestanol and lathosterol to cholesterol ratios, respectively.

Main Results:

  • High cholesterol absorption, indicated by higher cholestanol to cholesterol ratio, was significantly associated with increased cardiovascular death risk.
  • High cholesterol synthesis, indicated by higher lathosterol to cholesterol ratio, was significantly associated with decreased cardiovascular death risk.
  • No significant interaction was found between cholesterol metabolism markers and statin treatment in predicting cardiovascular death.

Conclusions:

  • High cholesterol absorption is linked to elevated cardiovascular risk in hemodialysis patients.
  • The findings do not support using cholesterol absorption rates to guide statin initiation in this patient group.
Abstract

Related Concept Videos

Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
116
Chronic Kidney Disease III: Interprofessional Care01:28

Chronic Kidney Disease III: Interprofessional Care

Chronic kidney disease (CKD) requires collaborative and comprehensive management. CKD progresses through stages and can lead to end-stage kidney disease (ESKD) if untreated. Interprofessional collaboration and patient education are crucial, enabling patients to manage their health and improve their quality of life.Diagnostic approach for chronic kidney diseaseThe diagnosis of CKD primarily focuses on the glomerular filtration rate (GFR), which assesses kidney function by measuring how well...
91
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
152
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
50
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
47
Hemodialysis I: Introduction01:25

Hemodialysis I: Introduction

Hemodialysis (HD) is a medical treatment that artificially removes waste products, excess fluids, and toxins from the blood when the kidneys are no longer able to perform these functions effectively. In this process, blood is filtered through a semipermeable membrane, allowing for the selective removal of waste while preserving necessary components like blood cells and proteins. Hemodialysis is typically performed in patients with end-stage renal disease (ESRD) or severe kidney...
327